CA2374788A1 - Inhibiteurs du facteur xa - Google Patents
Inhibiteurs du facteur xa Download PDFInfo
- Publication number
- CA2374788A1 CA2374788A1 CA002374788A CA2374788A CA2374788A1 CA 2374788 A1 CA2374788 A1 CA 2374788A1 CA 002374788 A CA002374788 A CA 002374788A CA 2374788 A CA2374788 A CA 2374788A CA 2374788 A1 CA2374788 A1 CA 2374788A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- 4alkyl
- ring
- independently
- member selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
L'invention concerne des nouveaux composés, leurs sels et les compositions associées, actifs contre le facteur Xa mammalien. Ces composés sont utilisés <i>in vitro</i> ou <i>in vivo</i> pour prévenir ou traiter les troubles de la coagulation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13583899P | 1999-05-24 | 1999-05-24 | |
US60/135,838 | 1999-05-24 | ||
PCT/US2000/014193 WO2000071515A2 (fr) | 1999-05-24 | 2000-05-24 | INHIBITEURS DU FACTEUR Xa |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2374788A1 true CA2374788A1 (fr) | 2000-11-30 |
Family
ID=22469944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002374788A Abandoned CA2374788A1 (fr) | 1999-05-24 | 2000-05-24 | Inhibiteurs du facteur xa |
CA002371904A Abandoned CA2371904A1 (fr) | 1999-05-24 | 2000-05-24 | Inhibiteurs du facteur xa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002371904A Abandoned CA2371904A1 (fr) | 1999-05-24 | 2000-05-24 | Inhibiteurs du facteur xa |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1185512A2 (fr) |
JP (2) | JP2003500391A (fr) |
AU (2) | AU5283600A (fr) |
CA (2) | CA2374788A1 (fr) |
WO (2) | WO2000071516A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2324153A1 (fr) | 1998-03-19 | 1999-09-23 | Ajinomoto Co., Inc. | Derives d'aminoisoquinoleine |
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
DE10139060A1 (de) | 2001-08-08 | 2003-02-20 | Merck Patent Gmbh | Phenylderivate |
PL213783B1 (pl) | 2002-03-13 | 2013-05-31 | Janssen Pharmaceutica Nv | Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
KR20040090981A (ko) | 2002-03-13 | 2004-10-27 | 얀센 파마슈티카 엔.브이. | 신규한 히스톤 디아세틸라제 저해제로서의카보닐아미노-유도체 |
AU2003218735B2 (en) | 2002-03-13 | 2009-03-12 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
PE20040167A1 (es) | 2002-03-28 | 2004-05-26 | Novartis Ag | Amidas del acido sulfamico |
CN100513398C (zh) | 2002-12-03 | 2009-07-15 | Axys药物公司 | 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物 |
EP1720844B1 (fr) * | 2003-04-03 | 2009-04-29 | MERCK PATENT GmbH | Derives pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl9-phenylamide) et composes similaires pour l'utilisation comme inhibiteurs du facteur xa pour le traitement de maladies thromboemboliques |
KR101204247B1 (ko) | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-이치환된 1h-피라졸 화합물 및 그의 시클린 의존성키나제 (cdk) 및 글리코겐 합성효소 키나제-3(gsk-3) 조정제로서 용도 |
DE102004014945A1 (de) * | 2004-03-26 | 2005-10-13 | Merck Patent Gmbh | Prolinylderivate |
AU2005266312C1 (en) | 2004-07-28 | 2011-06-16 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
CA2630717C (fr) | 2006-01-19 | 2015-02-24 | Janssen Pharmaceutica N.V. | Derives de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone desacetylase |
EP3541381B1 (fr) * | 2016-11-18 | 2022-12-28 | Merck Sharp & Dohme LLC | Inhibiteurs de facteur xiia |
BR112020015581A2 (pt) | 2018-01-31 | 2021-02-02 | Deciphera Pharmaceuticals, Llc | terapia de combinação para o tratamento de tumores estromais gastrointestinais |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
EP4327827A3 (fr) | 2019-12-30 | 2024-05-29 | Deciphera Pharmaceuticals, LLC | Formulations d'inhibiteurs de kinase amorphe et leurs procédés d'utilisation |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006694A1 (fr) * | 1996-08-16 | 1998-02-19 | Du Pont Pharmaceuticals Company | Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives |
EA003056B1 (ru) * | 1996-12-23 | 2002-12-26 | Дюпон Фармасьютикалз Компани | АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ |
-
2000
- 2000-05-24 AU AU52836/00A patent/AU5283600A/en not_active Abandoned
- 2000-05-24 JP JP2000619773A patent/JP2003500391A/ja active Pending
- 2000-05-24 CA CA002374788A patent/CA2374788A1/fr not_active Abandoned
- 2000-05-24 WO PCT/US2000/014209 patent/WO2000071516A2/fr not_active Application Discontinuation
- 2000-05-24 JP JP2000619772A patent/JP2003500390A/ja active Pending
- 2000-05-24 EP EP00937704A patent/EP1185512A2/fr not_active Withdrawn
- 2000-05-24 EP EP00937698A patent/EP1185511A2/fr not_active Withdrawn
- 2000-05-24 CA CA002371904A patent/CA2371904A1/fr not_active Abandoned
- 2000-05-24 AU AU52840/00A patent/AU5284000A/en not_active Abandoned
- 2000-05-24 WO PCT/US2000/014193 patent/WO2000071515A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2000071516A2 (fr) | 2000-11-30 |
EP1185512A2 (fr) | 2002-03-13 |
WO2000071516A3 (fr) | 2001-01-18 |
AU5283600A (en) | 2000-12-12 |
WO2000071515A2 (fr) | 2000-11-30 |
CA2371904A1 (fr) | 2000-11-30 |
JP2003500391A (ja) | 2003-01-07 |
WO2000071516B1 (fr) | 2001-03-01 |
AU5284000A (en) | 2000-12-12 |
EP1185511A2 (fr) | 2002-03-13 |
JP2003500390A (ja) | 2003-01-07 |
WO2000071515A3 (fr) | 2001-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2374788A1 (fr) | Inhibiteurs du facteur xa | |
US6638980B1 (en) | Inhibitors of factor Xa | |
US6545055B1 (en) | Inhibitors of factor Xa | |
US6632815B2 (en) | Inhibitors of factor Xa | |
US20030114448A1 (en) | Inhibitors of factor Xa | |
WO2001012600A1 (fr) | INHIBITEURS DU FACTEUR Xa | |
WO2000071509A1 (fr) | INHIBITEURS DU FACTEUR Xa | |
US6686368B1 (en) | Inhibitors of factor Xa | |
WO2002079145A1 (fr) | Composes de benzamide, inhibiteurs ddu factor xa | |
US20040082786A1 (en) | Piperazine based inhibitors of factor xa | |
CA2392576A1 (fr) | Inhibiteurs du facteur xa a base d'acides .beta.-amines, aspartiques et diaminopropioniques | |
US6673817B1 (en) | Inhibitors of factor Xa | |
US20040077690A1 (en) | Quaternary amidino based inhibitors of factor xa | |
WO2002026718A2 (fr) | Inhibiteurs du facteur xa à base de pyrimidine-4-one bicyclique | |
EP1322643A1 (fr) | Amides piperazine-2-un comme inhibiteurs du facteur xa | |
WO2001072725A1 (fr) | Inhibteurs aminosulfonyles bicycliques du facteur xa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |